CHINARES PHARMA(03320.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 2.19 billion, YoY increase of 5.26%
NewTimeSpace News: August 24, 2026, CHINARES PHARMA(03320.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 134.46 billion, increased by 1.96% YoY; Net Profit stood at CNY 5.02 billion, YoY decrease of 0.6%; Profit Attributable to Shareholders stood at CNY 2.19 billion, YoY increase of 5.26%; Basic Earnings Per Share (EPS) stood at CNY 0.35.
In terms of profitability, CHINARES PHARMA Gross Profit changed from CNY 21.51 billion in the same period last year to CNY 21.53 billion in the current period, increased by CNY 24.51 million; gross profit margin changed from 16.31% in the same period last year to 16.02% in the current period, decreased by 0.3 percentage points; net profit changed from CNY 5.05 billion in the same period last year to CNY 5.02 billion in the current period, decreased by CNY 30.13 million; net profit margin changed from 3.83% in the same period last year to 3.74% in the current period, decreased by 0.09 percentage points.
In terms of earnings quality, CHINARES PHARMA Operating Profit changed from CNY 7.04 billion in the same period last year to CNY 7.02 billion in the current period, decreased by CNY 18.44 million; Operating Profit Margin changed from 5.34% in the same period last year to 5.22% in the current period, decreased by 0.12 percentage points.
In terms of financial soundness, CHINARES PHARMA Debt-to-Asset Ratio changed from 60.94% in the same period last year to 59.46% in the current period, decreased by 1.49 percentage points; Total Equity changed from CNY 112.035 billion in the same period last year to CNY 119.324 billion in the current period, increased by CNY 7.29 billion; Current Liabilities changed from CNY 144.33 billion in the same period last year to CNY 146.96 billion in the current period, increased by CNY 2.63 billion; Quick Ratio stayed unchanged from 1.12 in the same period last year to 1.12 in the current period, remained flat.
By the close of trading on August 24, 2026, CHINARES PHARMA(03320) saw a loss of 2.18% in its share price, closing at HKD 4.705. The full-day turnover stood at HKD 52.31 million, showing significant volume increase, with the latest market capitalization at HKD 29.56 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
